Author

Yingyun Wang

Revolution Medicines (United States)ORCID 0009-0006-6917-0245Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Yingyun Wang1 paper · Genentech

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1 Research Focus:perturbation response prediction· 1

Frequent Co-Authors

Jennifer A. RothiD· 2 shared Mallika SinghiD· 2 shared Matthew G. ReesiD· 2 shared Matthew T. HolderfieldiD· 2 shared Melissa M. RonaniD· 2 shared Urszula N. WaskoiD· 2 shared A. Cole EdwardsiD· 1 shared Álvaro Curiel‐GarcíaiD· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 42 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Jennifer A. RothORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyCancer ResearchPeer-reviewedMay 22, 2026

Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-Mutated Melanoma

Mona Foth, Wontak Kim, Kayla T. O’Toole…·Martin McMahon

This study identifies RAS(ON) inhibitors effective against NRAS-mutated melanoma and reveals resistance mechanisms through Ppia and Map2k1 mutations.

5 citationstop 1%

humanexperimental assay

𝕏 PostBluesky

Cancer BiologyNaturePeer-reviewedApr 8, 2024

Tumor-selective effects of active RAS inhibition in pancreatic ductal adenocarcinoma

Urszula N. Wasko, Jingjing Jiang, Tanner C. Dalton…·Kenneth P. Olive

This study evaluates the therapeutic potential of RMC-7977, a broad-spectrum RAS inhibitor, in pancreatic ductal adenocarcinoma models, showing strong anti-tumor effects with minimal impact on normal tissues.

225 citationstop 1%

𝕏 PostBluesky